BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

INST develops hybrid compound to counter cancer cells

08 July 2020 | News

Polyoxometalates have evolved as a promising candidate for future metallodrugs for combating cancer



Scientists from the Institute of Nano Science & Technology (INST), Mohali have synthesized a novel inorganic-organic hybrid compound that can inhibit breast, lung, and liver cancer cells, opening up new possibilities for metallodrugs.

The solid compound based on phosphomolybdate cluster, an inorganic salt of phosphomolybdic acid, belongs to the Polyoxometalates (POMs) family, which had earlier been identified to have antitumor potential.

The team of scientists led by Dr. Monika Singh and Dr. Deepika Sharma has chalked out the mechanism by which the compound kills the cancer cells. The research has been published in the journal Dalton Transactions.

POMs are an evolving class of inorganic metal oxides, which over the last decades, established promising biological activities by the virtue of their great diversity in structures and properties.